| abstract |
The present invention is characterized in that it is obtained through a systematic mutation of a single amino acid of the wild type HMGB1 Box-A protein and has increased resistance to protease and thus has a more advantageous pharmacokinetic and pharmacodynamic profile. To polypeptide variants of HMGB-1 high affinity binding domain Box-A (HMGB1 Box-A) or biologically active fragments of HMGB1 Box-A. The invention also relates to the use of the polypeptide molecule of said HMGB1 Box-A for diagnosing, preventing, alleviating and / or treating a pathology associated with extracellular HMGB1. |